alexa Cardio-oncology: Cure The Cancer And Protect The Heart
ISSN: 2167-0870

Journal of Clinical Trials
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

6th World Pharmacists and Clinical Pharmacy Annual Congress
May 22-23, 2017 Chicago, USA

Sandra Cuellar
University of Illinois Hospital & Health Sciences, USA
Keynote: J Clin Trials
DOI: 10.4172/2167-0870-C1-012
Major therapeutic strides have been accomplished in oncology. Perhaps one of the best has been in breast cancer. Approximately, 3 million women are breast cancer survivors. However, there is a dark side to that statistic. Instead of women dying of breast cancer, data suggest that these women are dying of cardiovascular disease. Depending on the type of therapy, women can be up to 7 times more likely to develop cardiomyopathy compared to women who doesn’t receive cardiotoxic therapy. The epidemiology data and clinical research are changing the paradigm of cardiotoxicity in cancer therapy. Recently, the American Society of Clinical Oncology published recommendations on the prevention and management of cancer patients undergoing cardiotoxic therapies. Risk factor assessment, imaging and biomarkers have emerged as new strategies to assess and manage these patients. Perhaps, the most intriguing data that has been published in this arena is the use of global longitudinal strain (GLS). Measurement of GLS has demonstrated the ability to predict negative cardiac outcomes. It has the ability to detect subclinical damage to the heart. This concept is radically different than our historic methods of detecting cardiotoxicity. Historically, the preferred and most accepted imaging has been the multigated acquisition or MUGA. However, this time of imaging has limitations, in particular, the ability to detect subclinical cardiotoxicity. It can only detect cardiotoxicity that has already resulted in decline in ejection fraction. This presentation will discuss the epidemiology of cardiotoxicity in cancer patients and discuss the emerging strategies to detect, prevent and manage cardiotoxicity.

Sandra Cuellar is a Clinical Assistant Professor in the Department of Pharmacy Practice at the University of Illinois at Chicago (UIC) College of Pharmacy. She has been active in the field of hematology/oncology for 13 years. She is the Coordinator and Clinical Assistant Professor for Oncology Therapeutics. She has completed a Pharmacy Practice Residency at University of Kentucky Chandler Medical Center. Following her residency, she has completed a Specialty Oncology Residency at MD Anderson Cancer Center in Houston, Texas. She currently is the Clinical Pharmacist in the Out-Patient Cancer Center and is also the Director of the Oncology Specialty Residency program at UIC. She is an Editor for Journal of Hematology Oncology Pharmacy and is involved in research, consulting and publications in the field of hematology/oncology. Currently, she is a Member of the ASHP educational steering committee and serves as an ASHP Oncology Surveyor.

Email: [email protected]

image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version